Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 18/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 12/20 | 1.00 |
| ▸ | F2 | P00734 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21985912 | 0.92 | F11 (0.85) | F11KLKB1F2 | |
| SCHEMBL19682714 | 0.92 | F11 (1.00) | F11KLKB1F2 | |
| SCHEMBL21145591 | 0.91 | F11 (1.00) | F11KLKB1F2 | |
| SCHEMBL21145595 | 0.91 | KLKB1 (1.00) | F11KLKB1F2 | |
| SCHEMBL21145604 | 0.89 | KLKB1 (0.81) | F11KLKB1F2 | |
| SCHEMBL21145569 | 0.85 | KLKB1 (0.85) | F11KLKB1F2 | |
| SCHEMBL21145543 | 0.84 | F11 (1.00) | F11KLKB1F2 | |
| SCHEMBL17785396 | 0.84 | KLKB1 (0.84) | F11KLKB1F2 | |
| SCHEMBL19668198 | 0.84 | KLKB1 (1.00) | F11KLKB1F2 | |
| SCHEMBL24253352 | 0.82 | F11 (1.00) | F11KLKB1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002275-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-06 | — | — | US | claimed |
| CN-113387933-A | Pyrazole derivatives as plasma kallikrein inhibitors | 卡尔维斯塔制药有限公司 | 2021-09-14 | — | — | CN | claimed |
| EP-3760622-A1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2021-01-06 | — | — | EP | claimed |
| US-20190218205-A1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-07-18 | — | — | US | claimed |
| EP-4031547-B1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-07 | — | — | US | disclosed |
| US-20220002275-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-06 | — | — | US | disclosed |
| US-11180484-B2 | Pyrazole derivatives as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| CN-113387933-A | Pyrazole derivatives as plasma kallikrein inhibitors | 卡尔维斯塔制药有限公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-109311847-B | Pyrazole derivatives as plasma kallikrein inhibitors | 卡尔维斯塔制药有限公司 | 2021-07-06 | — | — | CN | disclosed |
| EP-3760622-A1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2021-01-06 | — | — | EP | disclosed |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-10-08 | — | — | US | disclosed |
| US-10730874-B2 | Inhibitors of plasma kallikrein and uses thereof | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| EP-3464271-B1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2020-05-13 | — | — | EP | disclosed |
| EP-3464271-B1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2020-05-13 | — | — | EP | disclosed |
| WO-2019178129-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| US-20190284182-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-19 | — | — | US | disclosed |
| US-20190218205-A1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | F11 78/4885KLKB1 1/4885F2 31/4885 |
| US-11180484-B2 | Pyrazole derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | F11 22/4885KLKB1 1/4885F2 17/4885 |
| US-20190284182-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | F11 78/4885KLKB1 1/4885F2 31/4885 |
| US-10730874-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | F11 78/4885KLKB1 1/4885F2 31/4885 |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | F11 73/4885KLKB1 1/4885F2 25/4885 |
| US-20220002275-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | F11 33/4885KLKB1 2/4885F2 23/4885 |
| US-20190218205-A1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | F11 22/4885KLKB1 1/4885F2 17/4885 |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | F11 78/4885KLKB1 1/4885F2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.